Introduction
The field of GLP-1 receptor agonist research is undergoing a period of rapid evolution. What began as a treatment for type 2 diabetes has expanded into obesity management and is now extending into liver disease, cardiovascular protection, neurodegenerative conditions, and substance use disorders. Simultaneously, the pharmacology is advancing from single-receptor targeting to dual and triple receptor agonism. This article reviews the current trajectory of GLP-1 RA research based on the latest published literature.
The Generational Evolution
GLP-1 receptor agonist development can be understood in three generations:
- First Generation: Selective GLP-1 RAs (exenatide, liraglutide, semaglutide) -- single receptor targeting with progressively improved efficacy and dosing convenience
- Second Generation: Dual GIP/GLP-1 agonists (tirzepatide) -- first-in-class dual agonist with superior weight loss outcomes
- Third Generation: Triple agonists (retatrutide, survodutide) -- targeting GLP-1, GIP, and glucagon receptors simultaneously
Retatrutide: The Triple Agonist
Retatrutide is the most advanced triple agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. Jastreboff et al. (2023) published the phase 2 trial results in the New England Journal of Medicine, showing the 12 mg dose achieved -24.2% mean body weight change at 48 weeks -- the largest weight reduction reported for any anti-obesity medication (PubMed: 37366315).
In a parallel type 2 diabetes study published in The Lancet by Rosenstock et al. (2023), retatrutide reduced HbA1c by up to 2.2% and body weight by up to 16.9% at 36 weeks, with 82% of participants in the highest dose group achieving HbA1c of 6.5% or less (PubMed: 37385280).
Why Add Glucagon?
The addition of glucagon receptor agonism may seem counterintuitive since glucagon raises blood glucose. However, glucagon agonism provides several metabolic benefits: increased energy expenditure through thermogenesis, enhanced lipid oxidation, reduced hepatic fat content, and additional appetite suppression. The key is balancing the hyperglycemic effect of glucagon with the glucose-lowering effects of GLP-1 and GIP agonism.
Expanding Beyond Metabolic Disease
A comprehensive 2025 review of emerging frontiers in GLP-1 therapeutics documented the expanding therapeutic landscape (PMC: 12389369):
Liver Disease
Phase 3 trial data for semaglutide in metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) were published in 2025, showing significant improvements in liver fibrosis and steatosis. This represents a major new indication given the lack of effective MASH treatments.
Cardiovascular Protection
The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events in people with obesity without diabetes. Meta-analyses of GLP-1 RA cardiovascular trials show consistent benefits on cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke.
Neurodegenerative Disease
GLP-1 receptors are expressed in the brain, and GLP-1 RAs cross the blood-brain barrier. Preclinical evidence demonstrates anti-inflammatory, neuroprotective, and neurogenesis-promoting effects. Clinical trials are underway for Alzheimer's and Parkinson's disease.
Substance Use Disorders
Multiple large-scale observational studies and ongoing clinical trials are investigating GLP-1 RAs for alcohol and substance use disorders. The rationale is based on the reward-modulating effects of GLP-1 receptor activation in the brain, which may reduce addictive behaviors.
Body Composition Concerns
A narrative review on GLP-1 RA research and future directions noted that while potent agents like tirzepatide and semaglutide demonstrate exceptional overall weight loss, they also cause significant lean mass reduction (PMC: 12303005). This has generated interest in combination approaches that pair GLP-1 RAs with agents that preserve or build lean mass, such as myostatin inhibitors or testosterone.
Oral Formulations
Currently, most GLP-1 RAs require subcutaneous injection. Oral semaglutide (Rybelsus) is available for diabetes at lower doses, and higher-dose oral formulations for obesity are in development. An oral formulation would dramatically expand accessibility and patient acceptance of these therapies.
Summary
The GLP-1 receptor agonist field is advancing on multiple fronts simultaneously: from single to triple receptor targeting, from metabolic disease to liver, cardiovascular, neurological, and addiction indications, and from injectable to oral formulations. Retatrutide's 24% weight loss in phase 2 trials has set a new benchmark, and the expanding indication landscape suggests that incretin-based therapies may become among the most widely prescribed drug classes in medicine. The coming years will determine which of these emerging applications translate into approved therapies.